Drug intelligence / Profile preview

KH-1

Development stage: Preclinical
Lead developer: Kalin Health

Overview

KH-1 is a novel nutraceutical developed by Kalin Health, LLC, composed of spermidine, spermidine derivatives, and probiotics. It is being investigated for its ability to stimulate autophagy, a cellular process believed to slow aging and mitigate its impacts. The primary indication under study is its effect on glucose homeostasis in non-diabetic adults with elevated blood glucose concentration, with potential benefits for reducing the risk of progression to diabetes. The drug also aims to evaluate biomarkers for inflammation, cardiovascular disease, insulin sensitivity, and overall well-being.

Targets

Neuraminidase

Beyond the preview

Go deeper on KH-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH-1.

Explore the full profile